<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01369199</url>
  </required_header>
  <id_info>
    <org_study_id>DK082864 HBRN IT Adult Trial</org_study_id>
    <secondary_id>U01DK082916</secondary_id>
    <secondary_id>U01DK082843</secondary_id>
    <secondary_id>U01DK082863</secondary_id>
    <secondary_id>U01DK082864</secondary_id>
    <secondary_id>U01DK082866</secondary_id>
    <secondary_id>U01DK082867</secondary_id>
    <secondary_id>U01DK082871</secondary_id>
    <secondary_id>U01DK082872</secondary_id>
    <secondary_id>U01DK082874</secondary_id>
    <secondary_id>U01DK082919</secondary_id>
    <secondary_id>U01DK082923</secondary_id>
    <secondary_id>U01DK082927</secondary_id>
    <secondary_id>U01DK082943</secondary_id>
    <secondary_id>U01DK082944</secondary_id>
    <secondary_id>P30DK050306</secondary_id>
    <secondary_id>A-DK-3002-001</secondary_id>
    <secondary_id>M01RR000040</secondary_id>
    <secondary_id>UL1TR000058</secondary_id>
    <secondary_id>UL1TR000004</secondary_id>
    <secondary_id>UL1TR001111</secondary_id>
    <secondary_id>UL1RR024986</secondary_id>
    <nct_id>NCT01369199</nct_id>
    <nct_alias>NCT01534611</nct_alias>
  </id_info>
  <brief_title>Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B</brief_title>
  <acronym>HBRN</acronym>
  <official_title>Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators evaluated the safety and efficacy of a short lead-in course (8 weeks) of
      entecavir followed by combination of entecavir plus peginterferon alfa-2a for 40 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the efficacy of treatment with 8 weeks of entecavir followed by 40 weeks of both
      entecavir and peginterferon in the treatment of chronic hepatitis B in hepatitis B &quot;e&quot;
      antigen (HBeAg) positive adults who are in the immune tolerant phase.

      To evaluate safety and sustained responses after treatment with entecavir and peginterferon
      alfa-2a in the treatment of chronic hepatitis B in HBeAg positive adults who are in the
      immune tolerant phase.

      A single arm treatment study of 8 weeks of entecavir followed by 40 weeks of both entecavir
      and peginterferon alfa-2a in adults with HBeAg-positive chronic hepatitis B with normal or
      near normal alanine aminotransferase (ALT) levels and high serum levels of hepatitis B virus
      (HBV) DNA (&quot;immune tolerant&quot; HBeAg-positive chronic hepatitis B). All participants followed
      for 48 weeks after treatment discontinuation (week 96 for those who completed treatment).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">February 14, 2017</completion_date>
  <primary_completion_date type="Actual">February 14, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants With HBeAg Loss (Lack of Detectable HBeAg) AND HBV DNA ≤1,000 IU/mL</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
    <description>Lack of data was considered to be treatment failure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs) Per Person-Year of Observation</measure>
    <time_frame>From first treatment to the end of treatment (up to 48 weeks) and the end of follow-up (up to 96 weeks)</time_frame>
    <description>The number of AEs includes both AEs and Serious Adverse Events (SAEs). The incidence is calculated as the number of AEs divided by the number of person-years of observation, which is the sum, across all participants, of the number of years between the start of treatment and the end of treatment, or the end of follow-up, respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs) Per Person-Year</measure>
    <time_frame>From first treatment to the end of treatment (up to 48 weeks) and the end of follow-up (up to 96 weeks)</time_frame>
    <description>The incidence is calculated as the number of SAEs divided by the number of person-years of observation, which is the sum, across all participants, of the number of years between the start of treatment and the end of treatment, or the end of follow-up, respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBeAg Loss</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBeAg Loss</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBeAg Seroconversion</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBeAg Seroconversion</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBsAg Loss</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBsAg Loss</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBsAg Seroconversion</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBsAg Seroconversion</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Alanine Aminotransferase (ALT) &lt;45 U/L for Men, &lt;30 U/L for Women</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With ALT &lt;45 U/L for Men, &lt;30 U/L for Women</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With ALT Normalization (Men &lt;30 U/L, Women &lt;20 U/L)</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With ALT Normalization (Men &lt;30 U/L, Women &lt;20 U/L)</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBV DNA ≤1000 IU/mL</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBV DNA ≤1000 IU/mL</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBV DNA &lt;20 IU/mL</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBV DNA &lt;20 IU/mL</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Detectable Antiviral Drug-resistance HBV Mutations</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Peginterferon and entecavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A combination of 8 weeks of entecavir followed by 40 weeks of both entecavir and peginterferon.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir and peginterferon</intervention_name>
    <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon 180 µg sq weekly during weeks 9-48 of treatment.</description>
    <arm_group_label>Peginterferon and entecavir</arm_group_label>
    <other_name>PEGASYS, peginterferon alfa 2a, Baraclude</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enrolled in &amp; completed the baseline evaluation for NCT01263587 or completed the
             necessary components of NCT01263587 by the end of baseline visit.

          -  &gt;18 years of age at the baseline visit (day 0). Patients &gt;50 years of age at baseline
             will need to have a liver biopsy as standard of care with hepatic activity index (HAI)
             ≤3 &amp; Ishak fibrosis score ≤1 within 96 weeks prior to baseline visit.

          -  Documented chronic HBV infection as evidenced by detection of HBsAg in serum for ≥24
             weeks prior to baseline visit OR at least one positive HBsAg &amp; negative anti-hepatitis
             B core (HBc) immunoglobulin (IgM) within 24 weeks prior to baseline visit OR at least
             one positive HBsAg &amp; two positive HBV DNA over a period of ≥24 weeks prior to baseline
             visit.

          -  Presence of HBeAg in serum at last screening visit within 6 weeks of baseline visit.

          -  Serum HBV DNA level &gt;10˄7 IU/mL on at least two occasions at least 12 weeks apart
             during the 52 weeks before baseline visit. One of the two HBV DNA levels must be
             within 6 weeks of baseline visit.

          -  ALT levels persistently ≤45 U/L in males, ≤30 U/L in females (approx. 1.5 times the
             upper limit of normal [ULN] range) as documented by at least three values: one taken
             28-52 weeks before baseline visit, one taken 6 to 24 weeks before the baseline visit,
             &amp; the final value within 6 weeks prior to baseline visit.

          -  No evidence of hepatocellular carcinoma (HCC) based upon alpha-fetoprotein (AFP) ≤20
             ng/mL at screening visit (up to 6 weeks prior to baseline visit). a. Participants who
             meet American Association for the Study of Liver Diseases (AASLD) criteria for HCC
             surveillance must have negative liver imaging as shown by ultrasound, computerized
             tomography (CT) or magnetic resonance imaging (MRI) within 28 weeks prior to baseline
             visit. b. Participants with AFP &gt;20 ng/mL must be evaluated clinically with additional
             imaging &amp; shown not to have HCC on CT or MRI before they can be enrolled.

        Exclusion Criteria:

          -  History of hepatic decompensation

          -  Evidence of decompensated liver disease prior to or during screening, including direct
             bilirubin &gt;0.5 mg/dL, international normalization ratio (INR) &gt;1.5, or serum albumin
             &lt;3.5 g/dL.

          -  Platelet count &lt;120,000/mm3, hemoglobin &lt;13 g/dL (males) or &lt;12 g/dL (females),
             absolute neutrophil count &lt; 1500 /mm3 (&lt;1000/mm3 for African-Americans) at last
             screening visit.

          -  Previous treatment with medications that have established activity against HBV
             including interferon &amp; nucleos(t)ide analogs ≥24 weeks. Patients with &lt;24 weeks of
             prior HBV treatment &amp; a wash-out period &gt;24 weeks are not excluded.

          -  Known allergy or intolerance to study medications.

          -  Females who are pregnant or breastfeeding. Females of childbearing potential unable or
             unwilling to use a reliable method of contraception during the treatment period.

          -  Renal insufficiency with calculated creatinine clearance &lt;50 mL/min at screening.

          -  History of alcohol or drug abuse within 48 weeks of baseline visit.

          -  Previous liver or other organ transplantation (including engrafted bone marrow).

          -  Any other concomitant liver disease, including hepatitis C or D. Non-alcoholic fatty
             liver disease (NAFLD) with steatosis &amp;/or mild to moderate steatohepatitis is
             acceptable but NAFLD with severe steatohepatitis is exclusionary.

          -  Presence of anti-hepatitis D virus (HDV) or anti-hepatitis C virus (HCV) (unless HCV
             RNA negative) in serum on any occasion in the 144 weeks prior to baseline visit.
             Presence of anti-HIV (test completed within 6 weeks prior to baseline visit).

          -  Pre-existing psychiatric condition(s), including, but not limited to: current moderate
             or severe depression, history of depression requiring hospitalization within the past
             10 years, history of suicidal or homicidal attempt within the past 10 years, history
             of severe psychiatric disorders as determined by a study physician.

          -  History of immune-mediated or cerebrovascular disease, chronic pulmonary or cardiac
             disease associated with functional limitation, retinopathy, uncontrolled thyroid
             disease, poorly controlled diabetes or uncontrolled seizure disorder, as determined by
             a study physician.

          -  Any medical condition that would, in the opinion of a study physician, be predicted to
             be exacerbated by therapy or that would limit study participation.

          -  Any medical condition requiring, or likely to require, chronic systemic administration
             of corticosteroids or other immunosuppressive medications during the course of this
             study.

          -  Evidence of active or suspected malignancy, or a history of malignancy within the 144
             weeks prior to baseline visit (except adequately treated carcinoma in situ or basal
             cell carcinoma of the skin).

          -  Expected need for ongoing use of any antivirals with activity against HBV during the
             course of the study.

          -  Concomitant use of complementary or alternative medications purported to have
             antiviral activity.

          -  Participation in any other clinical trial involving investigational drugs within 30
             days of the baseline visit or intention to participate in another clinical trial
             involving investigational drugs during participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Averell Sherker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Lok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIH Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23498</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hepbnet.org/</url>
    <description>Click here for more information about the Hepatitis B Research Network</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 6, 2011</study_first_submitted>
  <study_first_submitted_qc>June 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2011</study_first_posted>
  <results_first_submitted>March 7, 2018</results_first_submitted>
  <results_first_submitted_qc>June 29, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 3, 2018</results_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>Immune-tolerant hepatitis B</keyword>
  <keyword>HBV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data collected will be sent to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-supported data repository.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>At completion of HBRN project. Length of availability determined by NIDDK data repository.</ipd_time_frame>
    <ipd_access_criteria>Per NIDDK-supported data repository</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 15, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT01369199/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Twenty-eight (28) adults were enrolled at 11 clinical sites in the United States and Canada between 12/18/12 and 04/29/15.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Peginterferon and Entecavir</title>
          <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up for 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>End of Treatment (EOT)</title>
              <participants_list>
                <participants group_id="P1" count="26">1 withdrew consent before treatment,1 missed end of treatment (EOT) visit but completed follow-up.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Peginterferon and Entecavir</title>
          <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.2" lower_limit="22.2" upper_limit="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatitis B Virus (HBV) DNA</title>
          <units>log10 IU/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" lower_limit="7.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Participants With HBeAg Loss (Lack of Detectable HBeAg) AND HBV DNA ≤1,000 IU/mL</title>
        <description>Lack of data was considered to be treatment failure.</description>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Entecavir</title>
            <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBeAg Loss (Lack of Detectable HBeAg) AND HBV DNA ≤1,000 IU/mL</title>
          <description>Lack of data was considered to be treatment failure.</description>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit=".123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events (AEs) Per Person-Year of Observation</title>
        <description>The number of AEs includes both AEs and Serious Adverse Events (SAEs). The incidence is calculated as the number of AEs divided by the number of person-years of observation, which is the sum, across all participants, of the number of years between the start of treatment and the end of treatment, or the end of follow-up, respectively.</description>
        <time_frame>From first treatment to the end of treatment (up to 48 weeks) and the end of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Entecavir</title>
            <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events (AEs) Per Person-Year of Observation</title>
          <description>The number of AEs includes both AEs and Serious Adverse Events (SAEs). The incidence is calculated as the number of AEs divided by the number of person-years of observation, which is the sum, across all participants, of the number of years between the start of treatment and the end of treatment, or the end of follow-up, respectively.</description>
          <units>Events per person-year of observation</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>End of treatment (Up to 48 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" lower_limit="1.17" upper_limit="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of follow-up (Up to 96) weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" lower_limit="0.64" upper_limit="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Serious Adverse Events (SAEs) Per Person-Year</title>
        <description>The incidence is calculated as the number of SAEs divided by the number of person-years of observation, which is the sum, across all participants, of the number of years between the start of treatment and the end of treatment, or the end of follow-up, respectively.</description>
        <time_frame>From first treatment to the end of treatment (up to 48 weeks) and the end of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Entecavir</title>
            <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events (SAEs) Per Person-Year</title>
          <description>The incidence is calculated as the number of SAEs divided by the number of person-years of observation, which is the sum, across all participants, of the number of years between the start of treatment and the end of treatment, or the end of follow-up, respectively.</description>
          <units>SAEs per person-year of observation</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>End of treatment (Up to 48 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="NA">95% Confidence Interval (CI) around 0 not calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of follow-up (Up to 96 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".021" lower_limit=".003" upper_limit=".146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBeAg Loss</title>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Entecavir</title>
            <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBeAg Loss</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".036" lower_limit=".001" upper_limit=".183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBeAg Loss</title>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Entecavir</title>
            <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBeAg Loss</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".036" lower_limit=".001" upper_limit=".183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBeAg Seroconversion</title>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Entecavir</title>
            <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBeAg Seroconversion</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".036" lower_limit=".001" upper_limit=".183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBeAg Seroconversion</title>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Entecavir</title>
            <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBeAg Seroconversion</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".036" lower_limit=".001" upper_limit=".183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBsAg Loss</title>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Entecavir</title>
            <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBsAg Loss</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit=".123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBsAg Loss</title>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Entecavir</title>
            <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBsAg Loss</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit=".123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBsAg Seroconversion</title>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Entecavir</title>
            <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBsAg Seroconversion</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit=".123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBsAg Seroconversion</title>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Entecavir</title>
            <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBsAg Seroconversion</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit=".123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Alanine Aminotransferase (ALT) &lt;45 U/L for Men, &lt;30 U/L for Women</title>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Entecavir</title>
            <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Alanine Aminotransferase (ALT) &lt;45 U/L for Men, &lt;30 U/L for Women</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".571" lower_limit=".245" upper_limit=".628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With ALT &lt;45 U/L for Men, &lt;30 U/L for Women</title>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Entecavir</title>
            <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With ALT &lt;45 U/L for Men, &lt;30 U/L for Women</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".750" lower_limit=".551" upper_limit=".893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With ALT Normalization (Men &lt;30 U/L, Women &lt;20 U/L)</title>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Entecavir</title>
            <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With ALT Normalization (Men &lt;30 U/L, Women &lt;20 U/L)</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".393" lower_limit=".215" upper_limit=".594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With ALT Normalization (Men &lt;30 U/L, Women &lt;20 U/L)</title>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Entecavir</title>
            <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With ALT Normalization (Men &lt;30 U/L, Women &lt;20 U/L)</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".464" lower_limit=".275" upper_limit=".661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBV DNA ≤1000 IU/mL</title>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Entecavir</title>
            <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBV DNA ≤1000 IU/mL</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".929" lower_limit=".765" upper_limit=".991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBV DNA ≤1000 IU/mL</title>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Entecavir</title>
            <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBV DNA ≤1000 IU/mL</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit=".123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBV DNA &lt;20 IU/mL</title>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Entecavir</title>
            <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBV DNA &lt;20 IU/mL</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".179" lower_limit=".061" upper_limit=".369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBV DNA &lt;20 IU/mL</title>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Entecavir</title>
            <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBV DNA &lt;20 IU/mL</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit=".123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of Detectable Antiviral Drug-resistance HBV Mutations</title>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <posting_date>08/2020</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study entry (consent) to the end of follow-up (up to 96 weeks after treatment initiation).</time_frame>
      <desc>Asked at each visit. Expected symptoms/signs or common side effects of meds not reported (these are termed Adverse Effects). Below is a guide for recording adverse events which are at the discretion of the investigator.
Symptom or event requiring discontinuation of study medication.
New symptom or event requiring a written prescription for treatment.
New symptom or event resulting in a referral to another provider.
Grade 3 or 4 event per the NCI Common Toxicity Criteria.</desc>
      <group_list>
        <group group_id="E1">
          <title>Peginterferon and Entecavir</title>
          <description>Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon alfa-2a 180 μg subcutaneously (sq) weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment will be for 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Low white blood cells, platelets, and absolute neutrophil count</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Altered thyroid function</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Graves disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Heartburn and diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Poor appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Upset stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Decrease in appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Head cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Swollen lips</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection in right forefinger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intermittent finger joint pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Foul urine smell</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Frequent urination - prophylaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Penile yeast infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumococcal pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia (Hair loss)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Bruising on legs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hives</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Itchiness at injection site (intermittent)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Rash and itchiness on lower jaw</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Redness at injection site</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination of recruitment per Data and Safety Monitoring Board.
1 case with multiple central and local lab discrepancies was not considered to have HBeAg loss since central lab was always negative.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Steven Belle</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-624-5419</phone>
      <email>belle@edc.pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

